BACKGROUND: The known impairments of the cardiovascular system in Parkinson ́s disease (PD) are caused by autonomic dysfunction and manifested mainly in postural hypotension, chronotropic insufficiency, and reduced heart rate variability. Other dysfunctions, mainly stress response, arrhythmia occurrence, and heart morphology changes, are still the subject of research. OBJECTIVES: To assess the heart rate and blood pressure reaction during exercise, advanced measurements of heart volumes and mass using cardiac magnetic resonance (CMR), and occurrence of arrhythmias in PD patients. METHODS: Thirty PD patients (19 men, mean age 57.5 years) without known cardiac comorbidities underwent bicycle ergometry, electrocardiogram Holter monitoring and CMR. Exercise and CMR parameters were compared with controls (24 subjects for ergometry, 20 for CMR). RESULTS: PD patients had lower baseline systolic blood pressure (SBP) (117.8 vs. 128.3 mmHg, p < 0.01), peak SBP (155.8 vs. 170.8 mmHg, p < 0.05), and lower heart rate increase (49.7 vs. 64.3 beats per minute, p < 0.01). PD patients had higher indexed left and right ventricular end-diastolic volumes (68.5 vs. 57.3, p = 0.003 and 73.5 vs. 61.0 mL/m2 , respectively) and also indexed left and right ventricular end-systolic volumes (44.1 vs. 39.0, p = 0.013 and 29.0 vs. 22.0 mL/m2 , p = 0.013, respectively). A high prevalence of atrial fibrillation (8 subjects, 26.7%) was found. CONCLUSIONS: This novel study combining functional and structural approaches showed that PD is linked with weaker blood pressure and heart rate reaction during exercise, increased myocardial mass and heart volumes compared to controls, and a high prevalence of atrial fibrillation.
- MeSH
- elektrokardiografie MeSH
- fibrilace síní * komplikace MeSH
- lidé středního věku MeSH
- lidé MeSH
- magnetická rezonanční tomografie MeSH
- Parkinsonova nemoc * komplikace epidemiologie MeSH
- srdce MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- MeSH
- biomedicínský výzkum organizace a řízení MeSH
- hluboká mozková stimulace metody trendy MeSH
- lidé MeSH
- neurodegenerativní nemoci * epidemiologie patologie terapie MeSH
- neurologie * organizace a řízení MeSH
- Parkinsonova nemoc epidemiologie patologie terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- novinové články MeSH
BACKGROUND: Parkinson's Disease (PD) is a neurodegenerative disorder manifested by rest tremor, rigidity, bradykinesia, and postural instability. Recent pharmaco-epidemiological studies evaluating beta-adrenergic drug use and risk of PD have reported conflicting findings. OBJECTIVES: This systematic review and meta-analyses evaluate the association between beta-adrenergic (agonists and antagonists) drugs' use and PD. METHODS: An electronic literature search of eight databases was performed from inception to July 2021 to identify pharmaco-epidemiological studies (case-control and cohort) reporting the risk of PD in beta-adrenergic users compared to non-users. We used the generic inverse variance method and RevMan (5.3.5) to estimate pooled adjusted risk ratios (aRRs) of PD using a random-effects model. RESULTS: Of 3168 records, 15 studies (10 case-control; five cohort) with 6508,877 participants, including 87,011 PD cases, were included. In the pooled analysis (n = 10) including any beta-antagonist users, compared with non-users, the aRR for PD was 1.19 (CI: 1.05,1.35); for any beta-agonist users (n = 8) aRR for PD was 0.87 (CI: 0.78,0.97). Propranolol users had a significantly increased risk of PD (aRR:1.91; CI:1.20,3.06), whereas salbutamol use was associated with reduced risk of PD (aRR:0.95; CI:0.92,0.99). Significant heterogeneity (I2 >87%) was observed, but the majority (n = 13) of the studies were of high quality, based on the JBI tool. CONCLUSIONS: Beta-antagonist use was associated with a modestly increased risk of PD, whereas beta-agonist use was associated with a modest decreased risk of PD. Future epidemiological studies should address the issues of protopathic bias and indirect association using appropriate epidemiological methods.
- MeSH
- antiparkinsonika aplikace a dávkování farmakologie klasifikace MeSH
- diferenciální diagnóza MeSH
- levodopa aplikace a dávkování farmakologie klasifikace MeSH
- lidé MeSH
- Parkinsonova nemoc * dějiny diagnóza epidemiologie etiologie farmakoterapie terapie MeSH
- rizikové faktory MeSH
- věkové faktory MeSH
- Check Tag
- lidé MeSH
BACKGROUND AND AIM: Polypharmacy (concomitant use of 5-9 medicines) and hyperpolypharmacy (concomitant use of over 10 medicines) were observed to be more frequent in older adults (≥65 years) and associated with adverse outcomes. Their prevalence and risk in older patients with Parkinson's disease (PD) remain unknown. We aimed to synthesize the extant evidence on the prevalence and risk of polypharmacy and hyperpolypharmacy in older adults with PD. METHODS: A systematic literature search was performed in PubMed/MEDLINE, Scopus, and Embase databases to identify pertinent studies published from 2000 to July 2021. Observational studies reporting the prevalence and association with disease of polypharmacy/hyperpolypharmacy in older adults with PD were meta-analyzed. Pooled prevalence and odds ratio (OR) with 95% confidence intervals (CIs) were calculated. RESULTS: Out of the total 499 studies identified, 6 fulfilled the inclusion criteria and comprised 7,171 participants. The overall prevalence of polypharmacy and hyperpolypharmacy was 40% (95% CI: 37-44) and 18% (95% CI: 13-23), respectively. A meta-analysis of 4 studies indicated a significant association between polypharmacy (OR: 1.94, 95% CI: 1.26-2.62; p < 0.001) and PD. Hyperpolypharmacy was also strongly associated with PD (OR: 3.11, 95% CI: 2.08-4.14; p < 0.001). CONCLUSION: Polypharmacy (40%) and hyperpolypharmacy (18%) are highly prevalent and eventually increase the risk of drug-related problems in older adults with PD. Therefore, interventions that ensure rational geriatric pharmacotherapy are of critical importance for the older population with neurogenerative disorders.
- MeSH
- lidé MeSH
- odds ratio MeSH
- Parkinsonova nemoc * farmakoterapie epidemiologie MeSH
- polypharmacy * MeSH
- prevalence MeSH
- senioři MeSH
- Check Tag
- lidé MeSH
- senioři MeSH
- Publikační typ
- metaanalýza MeSH
- práce podpořená grantem MeSH
- systematický přehled MeSH
A growing aging population leads to a gradual increase in the number of patients with Parkinson's disease (PD). This study examines how perceived health, psychological distress, and subjective well-being evolve in older adults with PD. A cross-lagged study design was employed using data from Waves 4 and 6 of the Survey of Health, Aging and Retirement in Europe (SHARE). In total, 421 older adults diagnosed with PD at baseline (46% women; mean age 74.98 ± 9.05 years) were included in the study and were followed up after a four-year lag. Auto-regressive and cross-lagged associations between the measured variables were examined in reciprocal models. Individual differences in perceived health, psychological distress, and subjective well-being were relatively stable over the 4-year lag. A final reciprocal model with significant cross-lagged effects explained the underlying structure of the sample data well: χ2 (49) = 101.876, p < 0.001, CFI = 0.953, NFI = 0.935, RMSEA = 0.050, and AIC = 241.876. Increased difficulties in fulfilling instrumental activities and a lowered level of subjective well-being were particularly noticeable in older adults with PD during the four-year follow-up. Additional attention should be paid to helping older patients with PD cope better with their functional limitations and improve their sense of well-being.
- MeSH
- důchod MeSH
- lidé MeSH
- Parkinsonova nemoc * epidemiologie MeSH
- psychický distres * MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- stárnutí MeSH
- zdravotní stav MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
BACKGROUND: Parkinson's disease is a progressive neurodegenerative disease which causes health problem that affects more patients in the past few years. To be able to offer appropriate care, epidemiological analyses are crucial at the national level and its comparison with the international situation. AIM: The demographic description of reported patients with parkinsonism (including Parkinson's disease and atypical parkinsonian syndromes) according to the International Classification of Diseases (ICD-10) from the national health registries. METHODS: Retrospective analysis of data available from the National Health Information System-NHIS and the National Registry of Reimbursed Health Services (NRRHS). Analyzed epidemiological data are intending to determine the regional and specific prevalence of Parkinsonism in the Czech Republic. The International Classification of Diseases diagnoses (ICD-10) of G20 (Parkinson's disease-PD) and G23.1, G23.2, G23.3 (other degenerative disorders of basal ganglia), and G31.8 (another degenerative disease of basal ganglia) from the period of 2012 to 2018 were included into the analysis. RESULTS: We identified 78 453 unique patients from national registries in the period 2012 to 2018. Diagnoses of G20, G23.1, G23.2, and G31.8 were registered as the principal diagnoses in 76.6% of all individual patients. CONCLUSION: We have found a growing number of patients coded with ICD-10 of dg. G20, G23.1, G23.2, G23.3, or G31.8 (N = 27 891 in 2012, and N = 30 612 in 2018). We have proven regional differences in the prevalence of Parkinson´s diagnoses. Therefore we assume most likely also differences in the care of patients with PD based on the availability of specialty care centers.
- MeSH
- lidé středního věku MeSH
- lidé MeSH
- neurodegenerativní nemoci epidemiologie MeSH
- Parkinsonova nemoc diagnóza epidemiologie MeSH
- parkinsonské poruchy diagnóza epidemiologie MeSH
- prevalence MeSH
- registrace MeSH
- retrospektivní studie MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika MeSH
Alterations in complex behavioral patterns during the extended period of the COVID-19 pandemic are predicted to promote a variety of psychiatric disease symptoms due to enforced social isolation and self-quarantine. Accordingly, multifaceted mental health problems will continue to increase, thereby creating a challenge for society and the health care system in general. Recent studies show that COVID-19 can directly or indirectly influence the central nervous system, potentially causing neurological pathologies such as Alzheimer disease and Parkinson disease. Thus, chronic COVID-19-related disease processes have the potential to cause serious mental illnesses, including depression, anxiety, and sleep disorders. Importantly, mental health problems can foster systemic changes in functionally-linked neuroendocrine conditions that heighten a person's susceptibility to COVID-19 infection. These altered defense mechanisms may include compromised "self-control" and "self-care", as well as a "lack of insight" into the danger posed by the virus. These consequences may have serious social impacts on the future of COVID-19 survivors. Compounding the functionally related issues of altered mental health parameters and viral susceptibility are the potential effects of compromised immunity on the establishment of functional herd immunity. Within this context, mental health takes on added importance, particularly in terms of the need to increase support for mental health research and community-based initiatives. Thus, COVID-19 infections continue to reveal mental health targets, a process we must now be prepared to deal with.
- MeSH
- Alzheimerova nemoc epidemiologie prevence a kontrola virologie MeSH
- COVID-19 komplikace epidemiologie psychologie MeSH
- deprese epidemiologie prevence a kontrola psychologie MeSH
- duševní zdraví * MeSH
- fyzický odstup MeSH
- lidé MeSH
- náchylnost k nemoci psychologie MeSH
- pandemie MeSH
- Parkinsonova nemoc epidemiologie prevence a kontrola virologie MeSH
- péče o sebe psychologie MeSH
- přežívající psychologie MeSH
- SARS-CoV-2 patogenita MeSH
- sebekontrola psychologie MeSH
- sociální izolace psychologie MeSH
- úzkost epidemiologie prevence a kontrola psychologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- úvodníky MeSH
Parkinson's disease (PD) is most commonly manifested by the presence of motor symptoms. However, non-motor symptoms occur several years before the onset of motor symptoms themselves. Hallmarks of dysfunction of the respiratory system are still outside the main focus of interest, whether by clinicians or scientists, despite their indisputable contribution to the morbidity and mortality of patients suffering from PD. In addition, many of the respiratory symptoms are already present in the early stages of the disease and efforts to utilize these parameters in the early diagnosis of PD are now intensifying. Mechanisms that lead to the development and progression of respiratory symptoms are only partially understood. This review focuses mainly on the comparison of respiratory problems observed in clinical studies with available findings obtained from experimental animal models. It also explains pathological changes observed in non-neuronal tissues in subjects with PD.
- MeSH
- lidé MeSH
- mechanika dýchání fyziologie MeSH
- neurodegenerativní nemoci diagnóza epidemiologie patofyziologie MeSH
- Parkinsonova nemoc diagnóza epidemiologie patofyziologie MeSH
- poruchy dýchání diagnóza epidemiologie patofyziologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Idiopatická či sporadická Parkinsonova nemoc (PN) je považována za jednu z nejčastějších neurodegenerativních chorob. Toto onemocnění má poměrně heterogenní fenotypický charakter i původ: je pravděpodobné, že se na manifestaci PN podílí jak endogenní (genetické), tak i exogenní (environmentální) příčiny, je ovlivněna i mnohými dalšími faktory, skutečná patofyziologická příčina PN však dosud uspokojivě objasněna není. Je proto nepochybně mimořádně důležité primárně zmapovat všechna data, která mohou k pochopení vzniku PN napomoci. K těm patří nepochybně i data epidemiologická, mohou totiž poukázat i na faktory, které by dále mohly být experimentálně ověřovány. Je nutno zde konstatovat, že spolehlivá data týkající se prevalence a incidence PN jsou spíše výjimkou. Zatím bylo provedeno jen málo epidemiologických studií za pomoci validizovaných metod; pokud provedeny byly, jednalo se jen o relativně malé populace v geograficky omezených regionech a jiné studie byly prováděny pouze v oblastech s endemických výskytem parkinsonismu. Nicméně z dostupných studií lze říci, že prevalence PN a neurodegenerativního parkinsonismu vzrůstá s věkem, dále že odhadovaný rozptyl incidence je v rozpětí 10-50 případů na 100 000 ročně a pravděpodobná míra prevalence onemocnění je 100-300 nemocných na 100 000 obyvatel.
Idiopathic (sporadic) Parkinson's disease (PD) is one of the most frequent neurodegenerative disorders. The disease has heterogenous pfenotype and origin: both endogenous (genetic) and exogenous (enviromental) factors probably participate on manifestations of the PD and many other factors are involved. However, the exact pathophyziological cause has not been indentified yet. Therefore it is exceptionally important to collect all data which could help understanding the development of the Parkinson's disease. The epidemiological data can expose factors which can be further experimentally verified. It is essential to point out that relevant data about prevalence and incidence of PD are relatively rare. Just few epidemiological studies has been conducted yet using validated methods and if so, just small groups in geographically restricted areas were examined and other studies were contucted in regions with endemic incidence od parkinsonism. However, available studies suggest that the prevalence of PN and neurodegenerative parkinsonism increases with age, estimated incidence is in the range of 10-50 cases per 100 000 per year, and the probable prevalence rate is 100-300 patients per 100 000 inhabitants.
